NCT02999906View on ClinicalTrials.gov

Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2017

Primary Completion Date

December 31, 2021

Study Completion Date

June 30, 2022

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Oral Treprostinil

Sustained release oral tablets for three times daily administration

DRUG

Placebo

Placebo (sugar pill) for three times daily oral administration

Sponsors
All Listed Sponsors
lead

United Therapeutics

INDUSTRY